ArticleThe Journal of investigative dermatology2022
Angiogenin Released from ABCB5
Open access · hybridAbstract read
In one paragraph
Article in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Translational development of ABCB5Stem cell research & therapy · 2022Trial
- Angiogenin alleviates lipotoxicity-induced impairment of skin wound healing.Cellular & molecular biology letters · 2026Article
- The Role of Omics Techniques in Diabetic Wound Healing: Recent Insights into the Application of Single-Cell RNA Sequencing, Bulk RNA Sequencing, Spatial Transcriptomics, and Proteomics.Advances in therapy · 2025Review
- The Effectiveness of Recombinant Human Angiogenin during Skin Burn in CD-1 Mice.Bulletin of experimental biology and medicine · 2025Article
- The Differentiation and Regeneration Potential of ABCB5Journal of clinical medicine · 2025Review
- A Biologic and Physical Characterization of an Injectable Amniotic Membrane Designed for Treating Diabetic Foot Ulcers.Bioengineering (Basel, Switzerland) · 2024Article
- Postbiotic lactobacilli induce cutaneous antimicrobial response and restore the barrier to inhibit the intracellular invasion of Staphylococcus aureus in vitro and ex vivo.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Article
- Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation.International wound journal · 2023Review
- Signaling mechanisms underlying lymphatic vessel dysfunction in skin aging and possible anti-aging strategies.Biogerontology · 2023Review
- Angiogenin as a Possible Mediator of Macrophage-Mediated Regulation of Fibroblast Functions.Bulletin of experimental biology and medicine · 2023Article
- ABCB5Cytotherapy · 2023Article
- Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5Cells · 2023Article
- Molecular Pathophysiology of Chronic Wounds: Current State and Future Directions.Cold Spring Harbor perspectives in biology · 2023Review
- [Low-dose topical recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) therapy for chronic venous leg ulcers, 10-year follow-up].Dermatologie (Heidelberg, Germany) · 2023Article
- Skin-Derived ABCB5International journal of molecular sciences · 2022Review
- Recent advances of the nanocomposite hydrogel as a local drug delivery for diabetic ulcers.Frontiers in bioengineering and biotechnology · 2022Review
- Differential Effects of Calcium Alginate and Carboxymethylcellulose Wound Dressing Extracts on Human Sensory Neuron Regeneration and Secretome.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 4 countries.
Karmveer SinghDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Pallab MaityDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Albert Kallon KoromaDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Abhijit BasuDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Rajeev Kumar PandeyDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Seppe Vander BekenDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany; Bredent medical GmbH & Co KG, Senden, Germany.
Philipp HaasDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Linda KrugDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Adelheid HainzlDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Anca SindrilaruDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Christiane PfeifferDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Meinhard WlaschekDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Natasha Y FrankTransplant Research Program, Boston Children's Hospital, Boston, Massachusetts, USA; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts, USA; Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Markus H FrankTransplant Research Program, Boston Children's Hospital, Boston, Massachusetts, USA; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
Christoph GanssTICEBA GmbH, Heidelberg, Germany; RHEACELL GmbH & Co KG, Heidelberg, Germany.
András BánvölgyiDepartment of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Norbert WikonkálDepartment of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Sabine EmingDepartment of Dermatology and Venereology, University of Cologne, Cologne, Germany.
Irena PastarWound Healing and Regenerative Medicine Research Program, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Marjana Tomic-CanicWound Healing and Regenerative Medicine Research Program, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Mark A KluthTICEBA GmbH, Heidelberg, Germany; RHEACELL GmbH & Co KG, Heidelberg, Germany.
Karin Scharffetter-KochanekDepartment of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany. Electronic address: karin.scharffetter-kochanek@uniklinik-ulm.de.
Universität Ulm · DERheacell (Germany) · DESemmelweis University · HUUniversity of Miami · USBrigham and Women's Hospital · USEdith Cowan University · AUJohns Hopkins University · USUniversity of Cologne · DE
Funding
ABCB5-positive stem cells for LSCD therapyR01EY025794 · NEI · BOSTON CHILDREN'S HOSPITAL · PI NATASHA Y FRANK, Markus H. Frank · 2016 to 2026
$6.1MMultipotent ABCB5-positive cell therapeutics for corneal diseaseR24EY028767 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2018 to 2022
$5.9MDeveloping strategies for effective debridement in patients for venous leg ulcersR01AR073614 · NIAMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI KIRSNER, ROBERT SCOTT, TOMIC-CANIC, MARJANA · 2018 to 2023
$2.6MPerforin-2: The role of a novel antimicrobial protein in diabetic foot ulcersR01NR015649 · NINR · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI STRBO, NATASA, TOMIC-CANIC, MARJANA · 2015 to 2019
$2.6MUniversity of Miami Clinical Research Unit of the Diabetic Foot ConsortiumU01DK119085 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI KIRSNER, ROBERT SCOTT, LEV-TOV, HADAR · 2018 to 2022
$1.8MSkin-Intrinsic Immunosuppressive Mesenchymal Stem Cells and aGVHDR01HL161087 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H., FRANK, NATASHA Y · 2022 to 2025
$1.7MDevelopment of the Cellular Biomarker for Diabetic Foot UlcersRC1DK086364 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BREM, HAROLD, TOMIC-CANIC, MARJANA · 2009 to 2010
$903kIdentification and targeting of colon cancer initiating cellsI01BX000516 · VA · VA BOSTON HEALTH CARE SYSTEM · PI FRANK, NATASHA Y · 2011 to 2020
–ABCB5+ Dermal Stem Cells In Regenerative Wound HealingI01RX000989 · VA · VA BOSTON HEALTH CARE SYSTEM · PI FRANK, NATASHA Y · 2015 to 2017
–NEI NIH HHS R01 EY025794NEI NIH HHS R24 EY028767NHLBI NIH HHS R01 HL161087NIAMS NIH HHS R01 AR073614NIDDK NIH HHS RC1 DK086364NIDDK NIH HHS U01 DK119085NINR NIH HHS R01 NR015649RRD VA I01 RX000989
Abstract
Severe angiopathy is a major driver for diabetes-associated secondary complications. Knowledge on the underlying mechanisms essential for advanced therapies to attenuate these pathologies is limited. Injection of ABCB5
Indexed as
Diabetes Mellitus, Type 2Diabetic FootAnimalsMiceMice, Inbred StrainsNeovascularization, PathologicRibonuclease, PancreaticWound HealingangiogeninRibonuclease, Pancreatic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.